Form 4: Doximity Director Sells $1.27M in Stock

Doximity Director Timothy Cabral executed a pre-planned sale of 20,000 Class A shares for approximately $1.27 million after converting Class B shares and exercising options.

Summary

• Director Timothy S. Cabral, a Director at Doximity, Inc. (DOCS), engaged in multiple transactions involving the company's securities on August 15, 2025.
• Converted 20,000 shares of Class B Common Stock into an equal number of Class A Common Stock shares.
• Exercised stock options for 20,000 shares of Class B Common Stock at an exercise price of $2.21 per share. These options were granted on September 2, 2020, and vested in 36 equal monthly installments.
• Sold a total of 20,000 shares of Class A Common Stock in two separate transactions.
• The first sale involved 16,200 shares at a weighted-average price of $63.682 per share, generating approximately $1,030,948.40.
• The second sale involved 3,800 shares at a weighted-average price of $64.1889 per share, generating approximately $243,918.02.
• Total proceeds from the sales amounted to approximately $1,274,866.42.
• All sales were conducted automatically pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 13, 2025.
• Following these transactions, beneficial ownership of Class A Common Stock is 6,360 shares, and Class B Common Stock is 363,500 shares.

Sentiment

Score: 5

Explanation: The sentiment is neutral. While insider selling can sometimes be viewed negatively, the fact that it was executed under a Rule 10b5-1 plan mitigates concerns of opportunistic selling based on non-public information. It represents a routine liquidity event for a director.

Positives

• The stock sales were executed under a pre-arranged Rule 10b5-1 trading plan, indicating that the decision to sell was made in advance and not based on immediate, non-public information.
• The exercise of stock options indicates that the director realized value from previously granted equity compensation.

Negatives

• A director's sale of a significant number of shares, even if pre-planned, can sometimes be perceived by the market as a lack of conviction or a move towards diversification rather than continued investment in the company.

Future Outlook

The filing does not provide any forward-looking statements or guidance regarding the company's future financial performance or strategic direction. It solely reports past insider transactions executed under a pre-planned trading arrangement.

Industry Context

This Form 4 filing is a routine disclosure of insider trading activity and does not provide specific insights into broader industry trends or competitive dynamics within the healthcare technology sector. Insider sales are common for diversification and liquidity purposes.

Stakeholder Impact

• Shareholders may interpret the director's sale as a routine diversification or liquidity event, especially given the Rule 10b5-1 plan. However, some may view significant insider selling as a potential signal, though this is less likely with a pre-planned sale.

Key Dates

Recommendation

The filing reports a pre-planned insider sale by a director, which is a common occurrence for liquidity and diversification. While the sale is significant in value, its execution under a Rule 10b5-1 plan mitigates concerns of opportunistic selling based on non-public information. Without additional company-specific or market-wide information, this transaction alone does not suggest a change in the company's fundamental outlook or warrant a strong buy or sell recommendation.

Keywords

Doximity, DOCS, insider trading, Form 4, stock sale, director, Timothy Cabral, 10b5-1 plan, equity compensation